CAS NO: | 960203-27-4 |
生物活性 | Vortioxetine hydrobromide is a multimodal serotonergic agent, inhibits5-HT1A, 5-HT1B, 5-HT3A, 5-HT7receptor andSERTwithKivalues of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | Vortioxetine (Compound 5m) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7receptor and SERT with Kivalues of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. Vortioxetine displays antagonistic properties at 5-HT3Aand 5-HT7receptors, partial agonist properties at 5-HT1Breceptors, agonistic properties at 5-HT1Areceptors, and potent inhibition of SERT[1]. Vortioxetine is a partial h5-HT1Breceptor agonist with EC50of 460 nM and intrinsic activity of 22% using a whole-cell cAMP-based assay. Vortioxetine binds to the r5-HT7receptor with a Kivalue of 200 nM and is a functional antagonist at the r5-HT7receptor with an IC50of 2 μM in an in vitro whole-cell cAMP assay[5]. | ||||||||||||||||
体内研究 (In Vivo) | Vortioxetine (Lu AA21004) occupies the r5-HT1Breceptor and rSERT (ED50= 3.2 and 0.4 mg/kg, respectively) after subcutaneous administration and is a 5-HT3receptor antagonist[6]. Vortioxetine significantly increases cell proliferation and cell survival and stimulates maturation of immature granule cells in the sub granular zone of the dentate gyrus of the hippocampus after 21 days of treatment[3]. Vortioxetine does not cause cognitive or psychomotor impairment[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 379.36 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C18H23BrN2S | ||||||||||||||||
CAS 号 | 960203-27-4 | ||||||||||||||||
中文名称 | 盐酸沃替西汀 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(65.90 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |